|Bid||235.00 x 1100|
|Ask||310.00 x 900|
|Day's Range||286.99 - 291.69|
|52 Week Range||214.93 - 309.99|
|Beta (5Y Monthly)||0.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||290.41|
Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).
If the September Effect hits us again this year, our contributors have five stocks to suggest that you could pick up at a discount: Insulet (NASDAQ: PODD), Amazon (NASDAQ: AMZN), Shopify (NYSE: SHOP), Cresco Labs (OTC: CRLBF), and PubMatic (NASDAQ: PUBM). Medtronic and Tandem Diabetes were the first companies to offer next-generation, automated insulin delivery systems, but stiff competition from Insulet's Omnipod 5 could be coming soon.
Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.